Several checkpoint inhibitors that block PD-1, PD-L1 or CTLA-4 have been approved for therapy of solid cancers but, so far, checkpoint inhibitors have not shown convincing efficacy in MM [6–8]. The gene discussed is CTLA4; the disease is Miyoshi myopathy.